A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus–Pancreatic Cancer)

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511271-15-00

Acronym

WO39608

Enrollment

Registered

2024-04-04

Start date

2017-11-23

Completion date

2025-02-07

Last updated

2024-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic ductal adenocarcinoma (PDAC)

Brief summary

1. Objective response

Detailed description

1. Progression free survival, 2. Overall survival, 3. Overall survival at specific timepoints, 4. Duration of response, 5. Disease control, 6. Incidence, nature, and severity of adverse events and laboratory abnormalities, 7. Change from baseline in vital signs and ECG parameters, 8. Change from baseline in targeted clinical laboratory test results

Interventions

DRUGAbraxane 5 mg/ml powder for dispersion for infusion.

DRUGGemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung

DRUGRoActemra 20 mg/mL concentrate for solution for infusion

DRUGGemcitabin AqVida 38 mg/ml Pulver zur Herstellung einer Infusionslösung

DRUGGemcitabin Kabi 38 mg/ml Pulver zur Herstellung einer Infusionslösung

DRUGAvastin 25 mg/ml concentrate for solution for infusion.

DRUGATEZOLIZUMAB

DRUGTiragolumab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1. Objective response	—

Secondary

Measure	Time frame
1. Progression free survival, 2. Overall survival, 3. Overall survival at specific timepoints, 4. Duration of response, 5. Disease control, 6. Incidence, nature, and severity of adverse events and laboratory abnormalities, 7. Change from baseline in vital signs and ECG parameters, 8. Change from baseline in targeted clinical laboratory test results	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026